Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.42 |
| ▸ | DRD5 | P21918 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7951555 | 0.89 | DRD2 (0.43) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL585204 | 0.86 | BCL2 (0.43) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL577943 | 0.74 | CYP3A4 (0.45) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL3117291 | 0.74 | BCL2 (0.46) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30299229 | 0.72 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL1506557 | 0.72 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL577378 | 0.72 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL31028084 | 0.72 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL3108863 | 0.72 | KDM1A (0.41) | KDM1A | |
| SCHEMBL1451512 | 0.72 | MAOA (0.39) | DRD1DRD2DRD3DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921473-B1 | 1-CYAN-1-(7-METHOXYL-1-NAPHTYL) METHANOL ESTER COMPOUND AND PREPARATION METHOD AND USE THEREOF | JIANGXI SYNERGY PHARMACEUTICAL CO LTD (CN) | 2017-09-27 | — | — | EP | claimed |
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-0354094-B1 | INDOLONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SYNTHELABO (FR) | 1991-12-27 | — | — | EP | claimed |
| US-5010079-A | Treatment of psychological disorders | SYNTHELABO (FR) | 1991-04-23 | — | — | US | claimed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | claimed |
| JP-2073062-A | — | — | None | — | — | JP | disclosed |
| JP-2073075-A | — | — | None | — | — | JP | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| US-5010079-A | Treatment of psychological disorders | SYNTHELABO (FR) | 1991-04-23 | — | — | US | disclosed |
| US-5010079-A | Treatment of psychological disorders | SYNTHELABO (FR) | 1991-04-23 | — | — | US | disclosed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | disclosed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | disclosed |
| JP-H0273062-A | INDOLONE DERIVATIVE, ITS PREPARATION, AND DRUG CONTAINING IT | SYNTHELABO SA | 1990-03-13 | — | — | JP | disclosed |
| JP-H0273075-A | PIPERAZINE DERIVATIVE AND ITS PREPARATION | SYNTHELABO SA | 1990-03-13 | — | — | JP | disclosed |
| EP-0354094-A1 | Indolone derivatives, their preparation and their therapeutical use | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | DRD1 4863/4885DRD2 4885/4885DRD3 4879/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | DRD1 4699/4885DRD2 4735/4885DRD3 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.